Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Multifocal choroiditis (MFC) is an inflammatory disorder characterized by swelling of the eye (called uveitis) and multiple lesions in the choroid, a layer of blood vessels between the white of the eye and the retina. Symptoms include blurry vision, floaters, sensitivity to light, blind spots and mild eye discomfort. Though the cause is unknown, multifocal choroiditis is seen most frequently in women ages 20 to 60, and usually affects both eyes. MFC is generally treated with steroid medication that can be taken orally or injected into the eye. Multifocal choroiditis is a chronic condition, thus symptoms may return or worsen even after successful treatment.
Biomarker and diagnostic research for multifocal choroiditis has been reported in the published literature.
No clinical trials have been registered for multifocal choroiditis.
67 publications have been identified in PubMed for multifocal choroiditis. Research spans Case Report / Case Series (39%), Epidemiology / Natural History (20%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 26 | 39% |
Data assembled from 2 of 12 sources · Last updated Oct 4, 2026, 2:11 PM UTC
Genetic and Rare Diseases Info Center
13 |
20% |
Research summaries | 10 | 15% |
Testing and diagnosis research | 9 | 14% |
Clinical study results | 4 | 6% |
Other research | 2 | 3% |
Laboratory research | 2 | 3% |
Ferro Desideri L (2026). [PMID: 41109470](https://pubmed.ncbi.nlm.nih.gov/41109470/). *Am J Ophthalmol*. [Diagnostic / Biomarker]
Feo A (2026). [PMID: 42132560](https://pubmed.ncbi.nlm.nih.gov/42132560/). *Retina*. [Diagnostic / Biomarker]
Forte P (2026). [PMID: 42103031](https://pubmed.ncbi.nlm.nih.gov/42103031/). *Surv Ophthalmol*. [Review / Meta-Analysis]
Maury A (2026). [PMID: 41569740](https://pubmed.ncbi.nlm.nih.gov/41569740/). *Ocul Immunol Inflamm*. [Epidemiology / Natural History]
Samalia PD (2026). [PMID: 41642701](https://pubmed.ncbi.nlm.nih.gov/41642701/). *Am J Ophthalmol*. [Epidemiology / Natural History]
Feo A (2026). [PMID: 41490810](https://pubmed.ncbi.nlm.nih.gov/41490810/). *Am J Ophthalmol*. [Review / Meta-Analysis]
Gilead N (2026). [PMID: 41701337](https://pubmed.ncbi.nlm.nih.gov/41701337/). *Retina*. [Review / Meta-Analysis]
Joukainen E (2026). [PMID: 41852703](https://pubmed.ncbi.nlm.nih.gov/41852703/). *Clin Ophthalmol*. [Case Report / Case Series]
Belletti M (2026). [PMID: 41481499](https://pubmed.ncbi.nlm.nih.gov/41481499/). *Ocul Immunol Inflamm*. [Case Report / Case Series]
Cicinelli MV (2026). [PMID: 41271025](https://pubmed.ncbi.nlm.nih.gov/41271025/). *Am J Ophthalmol*. [Epidemiology / Natural History]